Product logins

Find logins to all Clarivate products below.


Eribulin

HALAVEN®

About HALAVEN®

  • Marketed by Eisai Inc.
  • Microtubule dynamics inhibitor
  • Treatment of refractory, metastatic breast cancer and liposarcoma

Review and approval status

November 15, 2010

First U.S. approval

March 17, 2011

First E.U. approval

Actual and expected launch:

  • 2023: Patent expiry: United States
  • 2024: SPC expiry: European Union
  • 2024: Patent expiry: Japan

API availability

*Source: Cortellis Generics Intelligence